Treatment of cytomegalovirus anterior segment infection with intravitreal injection of ganciclovir in adjunction with or without oral valganciclovir: a long-term results

Abstract We evaluated the therapeutic outcome of intravitreal injection (IVI) of ganciclovir with/without oral valganciclovir for cytomegalovirus (CMV) anterior segment infection. We enrolled 61 patients (61 eyes) with PCR-proven CMV anterior segment infection. IVI of ganciclovir (2 mg/0.05 mL) was...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Yu-Chun Cheng, Eugene Yu-Chuan Kang, Yih-Shiou Hwang, Ching-Hsi Hsiao
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/d454fd3de7174ea0b5c49de957918570
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:d454fd3de7174ea0b5c49de957918570
record_format	dspace
spelling	oai:doaj.org-article:d454fd3de7174ea0b5c49de9579185702021-12-02T14:06:11ZTreatment of cytomegalovirus anterior segment infection with intravitreal injection of ganciclovir in adjunction with or without oral valganciclovir: a long-term results10.1038/s41598-021-82637-y2045-2322https://doaj.org/article/d454fd3de7174ea0b5c49de9579185702021-02-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-82637-yhttps://doaj.org/toc/2045-2322Abstract We evaluated the therapeutic outcome of intravitreal injection (IVI) of ganciclovir with/without oral valganciclovir for cytomegalovirus (CMV) anterior segment infection. We enrolled 61 patients (61 eyes) with PCR-proven CMV anterior segment infection. IVI of ganciclovir (2 mg/0.05 mL) was given as a loading dose; subsequent use of oral valganciclovir (900 mg twice daily) was determined according to the severity of anterior chamber inflammation after injection. All eyes had IVI of ganciclovir, and 53 patients received oral valganciclovir as adjunctive therapy with a mean duration of 1.9 months to achieve disease remission. Repeated diagnostic aqueous taps were performed in 37 eyes with suspected recurrence, and CMV DNA was positive in 24 eyes. This therapeutic strategy afforded a median 50% recurrence-free survival time of 47.0 ± 8.12 months. The patients’ mean best corrected visual acuity, intraocular pressure and corneal endothelial cell counts stabilized or improved. Corneal transplantation before CMV infection diagnosis was identified as an independent risk factor for recurrence (hazard ratio 6.81, 95% confidence interval 1.21–38.23, P = 0.029). In patients with CMV anterior segment infection, the relative short-term therapeutic strategy, IVI of ganciclovir in adjunction with/without oral valganciclovir, effectively achieved a median recurrence-free survival time of nearly 4 years.Yu-Chun ChengEugene Yu-Chuan KangYih-Shiou HwangChing-Hsi HsiaoNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-7 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Yu-Chun Cheng Eugene Yu-Chuan Kang Yih-Shiou Hwang Ching-Hsi Hsiao Treatment of cytomegalovirus anterior segment infection with intravitreal injection of ganciclovir in adjunction with or without oral valganciclovir: a long-term results
description	Abstract We evaluated the therapeutic outcome of intravitreal injection (IVI) of ganciclovir with/without oral valganciclovir for cytomegalovirus (CMV) anterior segment infection. We enrolled 61 patients (61 eyes) with PCR-proven CMV anterior segment infection. IVI of ganciclovir (2 mg/0.05 mL) was given as a loading dose; subsequent use of oral valganciclovir (900 mg twice daily) was determined according to the severity of anterior chamber inflammation after injection. All eyes had IVI of ganciclovir, and 53 patients received oral valganciclovir as adjunctive therapy with a mean duration of 1.9 months to achieve disease remission. Repeated diagnostic aqueous taps were performed in 37 eyes with suspected recurrence, and CMV DNA was positive in 24 eyes. This therapeutic strategy afforded a median 50% recurrence-free survival time of 47.0 ± 8.12 months. The patients’ mean best corrected visual acuity, intraocular pressure and corneal endothelial cell counts stabilized or improved. Corneal transplantation before CMV infection diagnosis was identified as an independent risk factor for recurrence (hazard ratio 6.81, 95% confidence interval 1.21–38.23, P = 0.029). In patients with CMV anterior segment infection, the relative short-term therapeutic strategy, IVI of ganciclovir in adjunction with/without oral valganciclovir, effectively achieved a median recurrence-free survival time of nearly 4 years.
format	article
author	Yu-Chun Cheng Eugene Yu-Chuan Kang Yih-Shiou Hwang Ching-Hsi Hsiao
author_facet	Yu-Chun Cheng Eugene Yu-Chuan Kang Yih-Shiou Hwang Ching-Hsi Hsiao
author_sort	Yu-Chun Cheng
title	Treatment of cytomegalovirus anterior segment infection with intravitreal injection of ganciclovir in adjunction with or without oral valganciclovir: a long-term results
title_short	Treatment of cytomegalovirus anterior segment infection with intravitreal injection of ganciclovir in adjunction with or without oral valganciclovir: a long-term results
title_full	Treatment of cytomegalovirus anterior segment infection with intravitreal injection of ganciclovir in adjunction with or without oral valganciclovir: a long-term results
title_fullStr	Treatment of cytomegalovirus anterior segment infection with intravitreal injection of ganciclovir in adjunction with or without oral valganciclovir: a long-term results
title_full_unstemmed	Treatment of cytomegalovirus anterior segment infection with intravitreal injection of ganciclovir in adjunction with or without oral valganciclovir: a long-term results
title_sort	treatment of cytomegalovirus anterior segment infection with intravitreal injection of ganciclovir in adjunction with or without oral valganciclovir: a long-term results
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/d454fd3de7174ea0b5c49de957918570
work_keys_str_mv	AT yuchuncheng treatmentofcytomegalovirusanteriorsegmentinfectionwithintravitrealinjectionofganciclovirinadjunctionwithorwithoutoralvalgancicloviralongtermresults AT eugeneyuchuankang treatmentofcytomegalovirusanteriorsegmentinfectionwithintravitrealinjectionofganciclovirinadjunctionwithorwithoutoralvalgancicloviralongtermresults AT yihshiouhwang treatmentofcytomegalovirusanteriorsegmentinfectionwithintravitrealinjectionofganciclovirinadjunctionwithorwithoutoralvalgancicloviralongtermresults AT chinghsihsiao treatmentofcytomegalovirusanteriorsegmentinfectionwithintravitrealinjectionofganciclovirinadjunctionwithorwithoutoralvalgancicloviralongtermresults
_version_	1718392052811563008

Treatment of cytomegalovirus anterior segment infection with intravitreal injection of ganciclovir in adjunction with or without oral valganciclovir: a long-term results

Ejemplares similares